News

Human cells

Tailor-made genes

MIT News

April 30, 2025

Katie Galloway and her team developed synthetic gene circuits that enable more precise control of gene therapy. Their research, published in Cell Systems, could lead to new treatments for fragile X syndrome and other diseases caused by mutations in a single gene, ensuring more safe and effective therapeutic outcomes.

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Showing 201–210 of 624 stories

The NAEs Have It

MIT News

February 14, 2023

Cheers to Regina Barzilay and Roger Kamm, who are among the newest members of the National Academy of Engineering (NAE)! NAE election recognizes outstanding contributions to engineering research, practice, or education. Barzilay develops machine learning models that understand structures in text, molecules, and medical images, while Kamm is being honored for advancing understandings of mechanics in biology and medicine, and leadership in biomechanics.

A Holistic View of Cancer Research

MIT News

February 9, 2023

Along the way to becoming a physician-scientist, Spranger Lab alum Julian Zulueta is exploring cancer research and its impacts on individual lives. He believes that biomedical research is best framed through questions that center people’s experiences: “How do we think about their overall health, not just in treating the cancer, but also improving quality of life?”

Checking In(hibitors)

MIT News

February 2, 2023

Checkpoint inhibitors are effective against some types of cancers, working by stimulating exhausted T cells to attack tumors once again. But for lung cancer, this type of immunotherapy has shown mixed results. In a study of mice, the Spranger Lab traced the immune response to lung cancer back to the environment created by microbiota that naturally inhabit the lungs.

Ideally, “killer” T cells are activated in lymph nodes, where they interact with dendritic cells bearing tumor-derived antigens. The team found that while this encounter still took place in lymph nodes near the lungs, the outcome was different than in lymph nodes elsewhere in the body. Regulatory T cells—called into action by interferon gamma produced in response to commensal microbes in the lungs—prevented dendritic cells from activating killer T cells. The study, appearing in Immunity, was supported in part by the Koch Institute Frontier Research Program through the Casey and Family Foundation Cancer Research Fund.
 

Making His Biomark

Biomarker

February 1, 2023

Nobel laureate and landmark entrepreneur Phil Sharp recalls his roots as a rural farmer and basketball aspirant in a recent Biomarker feature, and reflects on the people who helped him forge a career in science. Sharp recounts the importance of mentoring, risk-taking, and forming expanded social networks for people like himself, who come from backgrounds where educational and professional opportunities in the field are unknown—and highlights exciting new science that keeps him up at night!
 

Protein Shake Up

MIT Spectrum

February 1, 2023

KI member and Biology department head Amy Keating designs protein-protein interactions to thwart disease. Thanks to advances in DNA sequencing and computational tools, her lab's work has evolved over the years to include synthesis of proteins not found in nature—but with potential to block many diseases including cancer. She is optimistic about the use of artificial intelligence and other tools in helping her team make predictions about their invented proteins and build new structures from smaller ones.

Beyond Prostate Cancer

MIT Koch Institute

January 31, 2023

The Yaffe Lab has discovered a mitotic mechanism that causes the combination of abiraterone, a standard treatment for prostate cancer, and Plk1-1 inhibitors to be more effective against prostate cancer than either drug alone. In a study appearing in Cancer Research and supported in part by the Bridge Project, they also found that the combination of abiraterone and the specific Plk1 inhibitor onvansertib was effective against a variety of other cancers beyond prostate cancer, including some types of pancreatic and ovarian cancers and acute myeloid leukemia.

Brush Up Your Combination Therapy

MIT News

January 26, 2023

A study appearing in Nature Nanotechnology describes how bottlebrush nanoparticles are able to co-deliver multiple cancer drugs to tumors. Working with former Charles W. (1955) and Jennifer C. Johnson Clinical Investigator Peter Ghoroghchian and others, KI member Jeremiah Johnson demonstrates how his lab’s signature technology allows researchers to adjust the ratio of drugs to maximize synergistic effects. The platform could be used to identify new combination therapies or improve effectiveness of already-approved drugs.

Farm Fresh Immunotherapy

Whitehead Institute

January 25, 2023

KI affiliate Tobi Oni is one of two Valhalla Fellows at the Whitehead Institute studying cancer and the immune system. Oni’s research focuses on how cell surface proteins and alpaca antibodies known as nanobodies can be used to disarm—and even fight back against—pancreatic cancer cells.

Bonjour, Live μ

MIT Biology

January 24, 2023

Live μ, the first instrument of its kind in the U.S., has landed in the Peterson (1957) Nanotechnology Materials Facility at the Koch Institute. The French-manufactured high-pressured freezer allows scientists to execute a cutting-edge strategy called correlative light electron microscopy (CLEM), where fluorescent light microscopy and electron microscopy images are taken of the same sample. The Live μ, along with the Peterson Facility’s growing suite of resources and workflows, is available to the MIT community.

Foretelling Lung Cancer Risk with AI

MIT News

January 20, 2023

Sybil—a new AI tool developed by KI member Regina Barzilay and Massachusetts General Hospital clinical collaborators Lecia Sequist and Florian Fintelmann—assesses a patient’s risk of lung cancer over six years by analyzing a single low-dose CT scan.

Unlike current methods, Sybil can make accurate predictions without using demographic or medical information or a radiologist’s annotation. The tool, described in the Journal of Clinical Oncology and profiled in The Washington Post, could be used to identify individuals who need additional testing and closer management and could be particularly useful given the rising incidence of lung cancer among non-smokers. MGH is launching a trial of Sybil, and researchers plan additional testing to ensure that it will maintain its accuracy across diverse populations.

Barzilay and Sequist will share project updates as part of SOLUTIONS with/in/sight: Algorithm & Views on May 4. The work is funded in part by the Bridge Project.